Why is Astrazeneca Phar falling/rising?

As of 28-Jul, Astrazeneca Pharma India Ltd is experiencing a price increase, currently at 8,927.05, reflecting a rise of 94.4 or 1.07%. Today's price summary indicates that the stock has outperformed its sector by 0.99%, although it is trading lower than its 5-day, 20-day, and 50-day moving averages. Despite a recent decline in investor participation, with delivery volume dropping by 50.91% against the 5-day average, the company has shown strong financial performance, including a significant net profit growth of 88.82% and positive results over the last two quarters. The stock has also generated a return of 24.68% over the past year, outperforming the BSE500 index consistently in the last three annual periods.
In the broader market context, Astrazeneca's short-term performance over the past week shows a decline of 2.20%, while the benchmark Sensex has decreased by 1.59%. This indicates that while the stock is currently rising, it has faced some short-term challenges compared to the overall market. The company's high management efficiency, low debt-to-equity ratio, and strong returns over the last three years contribute positively to its valuation. However, concerns about its high price-to-book value and relatively poor long-term growth prospects may temper investor enthusiasm, suggesting a mixed outlook for the stock's future performance.